Novel Therapeutics in Head and Neck Cancer

Bruno Bastos, MD
Assistant Professor
Florida International University / Baptist Health

Dr. Bruno Bastos is a medical oncologist with a focus in the treatment of patients with Genito-Urinary malignancies at Miami Cancer Institute in Miami, Florida. He treat patients with solid malignancies interested in participating in Phase I clinical trials. Dr. Bastos is an ABIM Board Certified Physician in Internal Medicine, Hematology and Medical Oncology. His training includes in addition to the formal internal medicine residency and Hematology-Oncology fellowship, an advanced fellowship in Development Therapeutics at the Dana-Farber Cancer Institute.

Dr. Bastos is a member of the scientific steering committee at Miami Cancer Institute, the lead physician in the Phase I multiple tumors clinic and also the Site Research Leader for US Oncology (USON) network at the Miami Cancer Institute. He provides supervision of the clinical staff and management of the clinical trial portfolio of the GU Oncology and Multiple Tumor/Phase I program at Miami Cancer Institute.

Dr. Basto’s clinical goal is to provide patients a personalized approach to their cancer care needs not only from the therapeutics standpoint but also from the social-psychological perspective.

His research interest includes development of targeted therapies to treat cancer. He is currently working on the use of multiple novel targeted therapies including GSK-3b inhibitors, KRAS G12c inhibitors, PARP inhibitors in HRD-deficiency tumors, PPAR-alpha antagonists and novel Immuno-Oncology drugs and combinations.

Outreach activities include membership on the Florida Society of Clinical Oncology Disparities Committee; Ad-Hoc Reviewer of fourteen journals and member of the ASCO Volunteer Corps.

JOIN HERE!

Objectives

At the end of the presentation, participants will be able to:

• Analyze standard of care for R/M HNSCC
• Recognize three main areas of drug development in R/M cancer
• Examine disparities gap in research

Faculty Disclosure

Dr. Bastos has indicated the following relevant financial relationships with commercial interests:

Financial Relationship                                          Commercial Interest/Organization
Advisor                                                                 Astellas, Seageb
Researcher                                                            Mirati, Janssen, Genetech, Er Squibbs & Sons

Planning Committee Disclosure

Dr. Lekakis, has indicated that he has no relevant financial relationships with commercial interests.

Target Audience

Faculty, Primary Care Physicians, APRNs, PharmD

Accreditation

The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.